Teva Announces Launch of Generic Pristiq® in the United States

Teva Pharmaceutical Industries has announced the launch of generic Pristiq®1 (desvenlafaxine) extended-release tablets, 25, 50 and 100 mg, in the U.S.

Desvenlafaxine extended-release tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder.

Desvenlafaxine extended-release tablets further enhance Teva’s portfolio of antidepressant products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Pristiq® had annual sales of approximately $883 million in the U.S. according to IMS data as of December 2016.